A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
June 6, 2025
End Date
June 9, 2030
Awarded By
Bristol-Myers Squibb Company
Start Date
June 6, 2025
End Date
June 9, 2030